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Abstract
Background: Establishing the effectiveness of patient decision aids (PtDA) requires evidence that PtDAs improve
the quality of the decision-making process and the quality of the choice made, or decision quality. The aim of this
paper is to review the theoretical and empirical evidence for PtDA effectiveness and discuss emerging practical
and research issues in the measurement of effectiveness.
Methods: This updated overview incorporates: a) an examination of the instruments used to measure five key
decision-making process constructs (i.e., recognize decision, feel informed about options and outcomes, feel clear
about goals and preferences, discuss goals and preferences with health care provider, and be involved in
decisions) and decision quality constructs (i.e., knowledge, realistic expectations, values-choice agreement) within
the 86 trials in the Cochrane review; and b) a summary of the 2011 Cochrane Collaboration’s review of PtDAs for
these key constructs. Data on the constructs and instruments used were extracted independently by two authors
from the 86 trials and any disagreements were resolved by discussion, with adjudication by a third party where
required.
Results: The 86 studies provide considerable evidence that PtDAs improve the decision-making process and
decision quality. A majority of the studies (76/86; 88%) measured at least one of the key decision-making process
or decision quality constructs. Seventeen different measurement instruments were used to measure decision-
making process constructs, but no single instrument covered all five constructs. The Decisional Conflict Scale was
most commonly used (n = 47), followed by the Control Preference Scale (n = 9). Many studies reported one or
more constructs of decision quality, including knowledge (n = 59), realistic expectation of risks and benefits (n =
21), and values-choice agreement (n = 13). There was considerable variability in how values-choice agreement was
defined and determined. No study reported on all key decision-making process and decision quality constructs.
Conclusions: Evidence of PtDA effectiveness in improving the quality of the decision-making process and decision
quality is strong and growing. There is not, however, consensus or standardization of measurement for either the
decision-making process or decision quality. Additional work is needed to develop and evaluate measurement
instruments and further explore theoretical issues to advance future research on PtDA effectiveness.
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As outlined in the introductory paper in this series of
manuscripts, 12 core dimensions for the assessment of
PtDAs were generated in 2005 by the International
Patient Decision Aids Standards (IPDAS) Collaboration,
and further reinforced by an extensive Delphi survey
undertaken by the IPDAS Collaboration [1]. One of
these 12 quality dimensions is the measurement of the
effectiveness of a patient decision aid (PtDA).
To establish the effectiveness of a PtDA, it is critical
to provide evidence that the PtDA improves two con-
structs: i) the quality of the decision-making process and
ii) the quality of the choice that is made (i.e., “decision
quality”). In the IPDAS Collaboration’s original 2005
Background Document [2], the chapter on establishing
the effectiveness set out key attributes for both the deci-
sion-making process and decision quality; and that work
subsequently prompted the Cochrane Collaboration’s
Systematic Review of Decision Aids to redesign the pre-
sentation of their results to follow these constructs and
attributes.
For the quality of the decision-making process, the core
attributes that should be measured include the extent to
which PtDAs help patients to:
￿ Recognize that a decision needs to be made (e.g., as
measured by items in the Preparation for Decision Mak-
ing Scale (PMDS) [3].
￿ Feel informed about the options and about the risks,
benefits, and consequences of the options (e.g., as mea-
sured by the “Feeling Uninformed” subscale of the Deci-
sional Conflict Scale[4]).
￿ Be clear about what matters most to them for this
decision (e.g., as measured by the “Unclear Values” sub-
scale of the Decisional Conflict Scale (DCS) [4]).
￿ Discuss goals, concerns, and preferences with their
health care providers (e.g., as measured by items in the
Perceived Involvement in Care Scale (PICS) [5]).
￿ Be involved in decision making (e.g., as measured by
the Control Preferences Scale (CPS) [6] and adaptations
of the CPS).
T h eq u a l i t yo ft h ec h o i c et h a ti sm a d e ,o rdecision
quality, is defined as the extent to which patients are
informed and receive treatments that reflect their goals
and treatment preferences [1,7]. It follows from this
construct definition that two core attributes should be
measured:
￿ Informed patient: This attribute is measured by
assessing a patient’s knowledge of the options and out-
comes. It is not assessed in terms of patient perceptions
of their knowledge level; instead, factual items are used
to assess objectively a patient’s understanding of the
information. This may, when applicable, include an
assessment of whether or not the patient holds realistic
expectations of risks and benefits.
￿ Concordance between what matters most to the
patient and the chosen option: Most approaches to mea-
suring this attribute require (1) the elicitation of a
patient’s goals and/or treatment preferences; (2) the
identification of the patient’s chosen or implemented
option; and (3) a calculation of the extent to which the
option best meets the patient’s stated goals or treatment
preferences.
These two constructs—the quality of the decision-
making process and the quality of the decision—are
equally relevant to PtDAs that address treatment as well
as screening decisions in which there are two or more
reasonable options. They are also applicable to other
settings—for example, in chronic disease when patients
are facing choices (e.g., whether or not to start a statin
for patients with diabetes).
Decisions to enact lifestyle changes that have a signifi-
cant behavior change component (such as smoking ces-
sation or weight loss) may require different or additional
support (e.g., supported self-management or motiva-
tional interviewing). Since the approaches used in these
kinds of health care situations often are not PtDAs, the
measures of effectiveness for these situations are not
covered in this review.
We note that other constructs—as either process or
outcome variables—have been used to evaluate the
effectiveness of PtDAs, such as decision self-efficacy,
decision regret, patient satisfaction with decision mak-
ing, and treatment choice. Furthermore, there are many
survey instruments and scales that cover one or more
attributes within the decision-making process and deci-
sion quality constructs. However, in this paper we focus
on the five decision-making process and the two deci-
sion quality attributes that are summarised above. Our
aims are to discuss the theoretical justification for using
these constructs—and their attributes—when evaluating
the effectiveness of PtDAs, to review current empirical
evidence on measurement of PtDA effectiveness (consid-
ering the different measurement instruments that have
been used to assess these key constructs), and to high-
light notable practical and research issues in measure-
ment that emerged from this analysis.
Theoretical justification for evaluating patient
decision aids on this quality dimension
Scientific rationale
Establishing the effectiveness of any health care inter-
vention, including PtDAs, is critical. There is consider-
able consensus that PtDAs should: a) improve the
quality of the decision-making process; and b) increase
decision quality or the likelihood that individuals choose
and/or receive health care interventions that are most
consistent with their informed and considered values
[1,8-13]. The Cochrane Collaboration’s Systematic
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to these key constructs and has found considerable evi-
dence that PtDAs improve these outcomes [14]. How-
ever, the field needs to continue to generate high-quality
evidence regarding the benefits and harms of PtDAs, as
well as their impact in vulnerable populations, and in a
range of health conditions and healthcare systems,
including different countries and cultures. We have
focused on the results of randomized controlled trials,
drawing extensively on those incorporated within the
Cochrane Collaboration’s review [14], as the gold stan-
dard for assessment of interventions.
Ethical rationale
PtDAs are viewed as a means of shifting from paternal-
ism to increased patient engagement in decision making,
including shared decision making (SDM), in healthcare.
SDM is a process by which a decision is made between
a patient (and their families or others), and one or
more healthcare professionals. It offers a model to
improve patient engagement, particularly in preference-
sensitive decisions in which there are multiple reasonable
options and in which the choice should be influenced by
patient goals and preferences.
As well as an ethical imperative to engage patients in
decisions about their own care, PtDAs can support
improvements in informed consent. King and colleagues
(2006) have argued that traditional informed consent
methods are inadequate to engage and inform patients
about treatment options in preference-sensitive decisions
[15]. SDM goes beyond information-giving to supporting
the formulation and communication of informed prefer-
ences. Thus, SDM may offer an ethically and legally sup-
ported means for fostering informed choice, including
transparent presentation of potential benefits and harms.
When usual care is compared to the use of PtDAs, usual
care has been shown to be inadequate for ensuring that
patients are informed and have realistic expectations [14].
The PtDA literature is relatively light on the explora-
tion of adverse effects, although such effects have been
posited. Adverse effects might include, for example, an
increase in inequalities (through being more accessible
to, or used by, well-educated patients), or increased con-
flict with public health priorities (through selection of
“less effective” interventions) [16]. For example, well
informed patients may select to forego colon cancer
screening or other interventions that have been shown to
be effective in prolonging life or other outcomes. To the
extent that “pay-for-performance” or other quality mea-
surement initiatives for health care providers or health
systems focus on the public health priorities as opposed
to the individual’si n f o r m e dc h o i c e s ,t h i sm a yr e s u l ti n
increased tension and conflict with the goals of PtDAs.
Other adverse effects might include increased patient
anxiety when patients are faced with clinical uncertainty
[ 1 7 ] ,o ra r eo f f e r e da nu n e x p e c t e dr o l ei nd e c i s i o nm a k -
ing and are initially wary of engaging in decision making
[18], or feel unsupported or ‘abandoned’ if decision mak-
ing is not actually shared but is unduly delegated to
patients[19]. Adverse effects could also occur if PtDAs
are not well-developed, or become out-of-date, and
therefore might bias decisions.
Conceptual rationale
Measures of the “quality of the decision-making process”
and “decision quality” highlighted in this manuscript
have underpinnings in theories of decision making.
Normative theories of decision making, such as subjec-
tive expected utility theory, are based on the ideal that
patients approach decisions rationally and are able to
weigh the risks and benefits of all available interventions
[20]. Descriptive theories of decision making, such as
prospect theory, demonstrate that humans are subject to
cognitive biases that cause decision making to deviate
from the normative/rational ideal [21]. For example, a
well-known cognitive bias has to do with the effects of
framing, where people tend to be risk-averse when sta-
tistics are presented as gains and risk-seeking when they
are presented as losses [22]. These kinds of biases can
threaten a person’s ability to acquire accurate knowledge
or to make a decision concordant with their values, thus
threatening the quality of their decision. The Dual-
Process Theory of decision making argues that people
make decisions either “intuitively” (i.e., quickly drawing
on past experiences), or “reasonably” (i.e., using a
thoughtful, analytic approach), with the latter being less
subject to many of the cognitive biases[21]. PtDAs are
designed to encourage a more deliberative decision-making
process that can help to minimize cognitive bias. If a more
reasoned, normative approach is pursued, it follows that
the actual choice is more likely to be informed and value
concordant, resulting in higher “decision quality.”
Although conceptually many of these theories share
similar underpinnings (e.g., an emphasis on information
and the use of deliberative processes to align choices with
goals), there is considerable debate about how that is oper-
ationalized into specific measures. The debate involves not
only how to measure the construct (e.g., measuring
patients’ preferences using the standard gamble in formal
decision analysis versus using attitude scales), but also
when these are measured. For example, Elwyn and Miron-
Shatz (2010) have argued that it is best to measure the
quality of the decision-making process before and immedi-
ately after exposure to the PtDA. They argue against retro-
spective assessments that are subject to hindsight bias,
particularly following adverse clinical outcomes, and
might distort the assessment of the decision-making pro-
cess [23]. Others point to theories, such as differentiation
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continue to react to and interpret the decision after it is
taken and that it is important to measure regret and other
variables after the decision has been made [24].
Which outcomes to measure are also being debated. A
key goal of health care is to improve health outcomes,
and many outside the field ask about the impact of
PtDAs on health outcomes. There are several challenges
to the use of clinical health outcomes (such as pain, over-
all quality of life, or mortality) to assess the effectiveness
of PtDAs. First, the nature of the situation addressed by
P t D A sr e q u i r e st h a tt h e r eare multiple reasonable
options, often with different potential effects (positive or
negative) on health outcomes. Thus, by definition, there
is usually not one clearly superior treatment or interven-
tion. Second, many of these decisions are made under
uncertainty, and are essentially making a bet. The appro-
priate evaluation of a bet depends on the odds, not the
outcome. For example, a patient may choose to have sur-
gery, feeling that the benefits outweigh the harms, and
yet may suffer a severe, unanticipated complication dur-
ing the procedure. This bad outcome should be used to
improve the delivery of the procedure, but it should not
reflect poorly on the decision to have surgery. A third
challenge with using health outcomes as a measure is
that this often requires setting a global standard (e.g.,
longer life is always better, or less pain is always better).
However, studies have shown that patients vary in their
willingness to trade off quality of life and quantity of life.
For example, some patients may elect to forego che-
motherapy if their desire to avoid short-term severe side
effects outweighs their desire for increasing short-term
survival. In sum, to the extent that patients feel differ-
ently about potential health outcomes, it is necessary to
measure the effectiveness of PtDAs by the extent to
w h i c ht h e ye n a b l ep a t i e n t st oa c h i e v et h eo u t c o m e st h e y
most desire while also avoiding those they most dislike.
Policy rationale
There are several recent, widespread health policy dri-
vers across several different countries that focus on
patient engagement, PtDAs, and SDM, emphasizing the
need for a robust evidence base. For example, in the
United States, the Institute of Medicine and the
National Priorities Partnership (NPP) have identified
patient and family engagement and patient-centered
care—defined in part as ensuring that patient are
informed, meaningfully involved in treatment decisions,
and receive treatments that reflect patients’ goals, needs,
and preferences—as one of six national health care prio-
rities [25,26]. This has had wide impact; for example,
prompting the National Quality Forum (NQF), the US
body that endorses performance measures, to examine
their endorsed measures: none were related to SDM,
and hence the NQF has identified SDM as a priority
area for additional measure development [27].
Similarly, SDM (“Nothing about me, without me”)i s
included within the latest UK Government health policy
[28], and is embedded in legislation [29]. The Depart-
ment of Health has commissioned an extensive program
of development of PtDAs [30]. Further description on
policy developments internationally can be found in a
special 2011 issue of The German Journal for Quality in
Healthcare [31].
The policy perspective creates pressure to measure an
additional variable — costs. If health systems are to fund
access to PtDAs, then they want to know the intervention
is not only effective but also cost-effective. The impact of
PtDAs on utilization has been demonstrated in a small
number of decisions, with patients less likely to select
more invasive options where such choices exist (e.g., active
surveillance or surgery for benign prostate disease) [14]. A
recent large demonstration project in the US found that
widespread use of decision aids in hip and knee osteoar-
thritis led to reduced surgical rates and reduced costs [32].
However, the impact on cost seems to depend on baseline
utilisation [28]. Hence, cost alone is neither a sufficient
nor an appropriate core measure for effectiveness, which
should be based upon improved quality of the decision-
making process and decision quality. Nevertheless, as
implementation efforts expand, examining the impact on
costs and developing more sophisticated assessment of
cost-effectiveness, based on appropriate outcomes, will be
increasingly important.
Empirical evidence
Methods
Data were used from the 2011 Cochrane Collaboration
systematic review of PtDAs to assess what is known
about the impact of PtDAs on the quality of the decision
making process and the quality of the choice that is
made (i.e., decision quality) [14]. This review included
86 randomized controlled trials (RCTs) comparing indi-
vidual PtDAs for treatment or screening decisions to
usual care and/or alternative interventions.
We extended the Cochrane Collaboration’sr e v i e wb y
gathering additional information about the measurement
instruments used to assess key outcomes in each of the
86 studies. Two reviewers independently abstracted
information, such as the medical condition covered,
mode of administration of the measurement instru-
ments, and whether or not the instrument covered any
of the five decision-making process attributes (i.e.,
recognize decision, feel informed, clear values, discuss
goals with health care provider, be involved) or the two
decision quality attributes (i.e., knowledge (including
realistic expectations), and concordance). Detailed narra-
tive data on the instruments and how they were used
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from each reviewer and reconciled any discrepancies by
consulting the full text of the article. The lead authors
(KS and RT) adjudicated differences across reviewers
that were not able to be resolved by consulting the full
text.
In many cases, the actual items from the measurement
instruments were not included in the articles, which
made it difficult to code accurately. If an instrument was
used in more than one study, additional articles were
retrieved and reviewed in order to determine whether or
not items covered one or more of the attributes. If any of
the items included in the instrument elicited information
on a particular attribute, we considered it covering that
attribute, even if it was not reported on separately. For
example, if a study only reported the total score for the
Decisional Conflict Scale, we still considered that it cov-
ered two of the decision-making process attributes: “feel
informed about options, risks and benefits” and “be clear
about values.”
The data were collected in structured Excel spread-
sheets and after the data were reconciled they were
entered into an SPSS file (IBM SPSS Statistics, version
20.0) for analysis. Descriptive statistics were used to
examine the frequency of use of the different attributes
and measurement instruments.
Frequency of inclusion of key outcomes in decision aid
studies
We abstracted 180 cases in which a reported outcome
mapped onto one or more of the decision-making pro-
cess or decision quality attributes. The majority of studies
in the Cochrane Collaboration’s review (76/86; 88%)
reported on one or more outcomes that assessed deci-
sion-making process or decision quality attributes. On
average, each study reported on 2.1 measurement instru-
ments that captured one or more of the attributes (ran-
ging from 0 to 5 instruments per study). Most of the
studies that did not report on any of these core attributes
only reported the impact on choices or uptake of treat-
ment, without any examination of whether the change in
rates reflected an increase or decrease in concordance.
Measures of the quality of the decision-making process
Our review identified 17 different measurement instru-
ments used to assess aspects of the decision-making pro-
cess. The most common was the Decisional Conflict Scale
(DCS) [4], used in 47 studies, followed by adaptations of
the Control Preferences Scale (CPS) [33], used in nine stu-
dies. All other instruments were used in four studies or
fewer. The other named instruments that covered one or
more of the decision-making process attributes included
the Autonomy Preference Index (API) [34], COMRADE
[35], Decision Satisfaction Inventory (DSI) [36], Perceived
Decision Control [37], Perceived Involvement in Care
Scale (PICS) [5], Preparation for Decision Making Scale
(PDMS) [3], Problem Solving Decision Making Scale
(PSDM) [38], Satisfaction with Decision Making Process
(SDMP) [39], and Satisfaction with Decision (SWD) [40].
Although the vast majority of trials used patient surveys,
one used qualitative methods, involving the coding of
audio-taped consults, to assess the level of Informed
Decision Making [41].
We did not find a single measurement instrument that
covered all of the decision-making process attributes.
The Preparation for Decision Making Scale covers the
most, and includes items that cover four of the five
attributes (it does not have items that assess the extent
to which patients feel informed about options and out-
comes) [42]. Table 1 shows how often each decision-
making process attribute was measured across the 86
studies, an example of an item used to measure the
attribute, and the named measurement instruments
used. The attributes of “feeling informed about options
and outcomes” and “clear about values” are the most
commonly assessed (mainly assessed using the DCS),
and whether patients “recognize that there is a decision
to be made” and whether they “discuss their goals and
preferences with their healthcare provider” are the least
commonly assessed.
Impact of PtDAs on decision-making process
The Cochrane Collaboration’sr e v i e wp r e s e n t sp o o l e d
data on three of this constuct’s key attributes, and
reports that PtDAs result in: a) a reduction in feeling
uninformed (n = 17; mean difference = -6.4 of 100; 95%
CI -9.2 to -3.7) assessed with the “Feeling Uninformed”
subscale of the Decisional Conflict Scale; b) a reduction
in feeling unclear about personal values (n = 14; mean
difference = -4.8; 95% CI -7.2 to -2.4) assessed with a
subscale of the DCS; and c) reduction in provider con-
trolled decision making (n = 11; RR = 0.61; 95% CI 0.5
to 0.8). There were no data reported in the Cochrane
Collaboration’s review on the effectiveness of PtDAs in
helping patients to recognize that a decision needs to be
made, or to discuss values and preferences with their
health care provider [14].
Measures of decision quality
Across the 86 studies, we found 59 cases in which mea-
surement instruments assessed patients’ knowledge and 21
that included items that assessed realistic expectations.
Most of the knowledge questionnaires were multiple
choice or true-false in format, and only two were “named”
measurement instruments (Breast Cancer Information
T e s t[ 4 3 ]a n dB r e a s tC a n c e rP r e v e n t i o nQ u e s t i o n n a i r e
[44]). More than half (36/59, or 60%) of the knowledge
instruments were created anew for the study.
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CONSTRUCTS
Recognize Decision Feel Informed Feel Clear about Values Discuss Goals with HCP Be Involved
Frequency of
use
13 55 56 8 33
Unique
measurement
instruments
65 5 5 2 0
Survey
instrument,
sample item,
and response
set
PDMS: Did this educational material
help you realize that a decision
needs to be made? (“Not at all” to
“A great deal”)
DCS: I understand the
options for treatment of X.
(“Strongly agree” to
“Strongly disagree”)
DCS: It is clear which benefits
and harms matter most to me.
(“Strongly agree” to “Strongly
disagree”)
PICS: My doctor encouraged me to talk
about my personal concerns related to my
medical symptoms (“Strongly agree” to
“Strongly disagree”)
CPS: Please select the option
that reflects how you would
like your medical decisions to
be made:
￿ I prefer to make the final
decision
￿ I prefer to make the final
decision after seriously
considering my doctor’s
opinion
￿ I prefer that my doctor and I
share responsibility for the
decision
￿ I prefer that the doctor
makes the decision after he/
she seriously considers my
opinion
￿ I prefer my doctor to make
the decision
Named
measurement
instruments
used
SWD (n=4) PICS (n=3) PDMS (n=2) DCS (n=45) SWD (n=4)
SDMP (n=4) DSI (n=1)
DCS (n=46); SWD (n=3); SDMP
(n=3); PDMS (n=2)
PICS (n=3); PDMS (n=2) CPS (n=9); SDMP (n=3); API
(n=2); COMRADE (n=1); DSI
(n=1); PSDM (n=1); PDC (n=1)
Legend: HCP=health care provider; PDMS=Preparation for Decision Making Scale; DCS=Decisional Conflict Scale; PICS=Perceived Involvement in Care Scale; CPS=Control Preferences Scale (including adaptations);
SWD=Satisfaction with Decision; SDMP=Satisfaction with Decision Making Process; API=Autonomy Preference Index; DSI=Decision Satisfaction Inventory; PSDM=Problem Solving Decision Making Scale;
PDC=Perceived Decision Control.
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1Fewer studies (n = 13) reported on concordance or
values-choice agreement. Six of these used the Multidi-
mensional Measure of Informed Choice (MMIC)
[45-50]. This approach differed from study to study, but
generally included an assessment of knowledge (those
who score above a level set ap r i o r iwere considered
informed), clear values (e.g., those who score 25 or less
on the “Unclear Values” subscale of the DCS), and clear
intention (those patients who were able to state a clear
treatment preference as opposed to being unsure). A
composite score of informed choice indicated the per-
centage of patients who were informed, had clear values,
and a clear intention.
The other seven studies used different approaches to
calculate concordance. Two of the studies used a
straightforward approach and measured concordance by
calculating the percentage of patients who received
treatment that matched the patients’ stated treatment
preference [51,52]. Frosch (2008) used one item to
represent men’s preferences, namely their concern about
the risk of dying of prostate cancer, and then looked at
whether the mean scores on that item differed between
men who did or did not get screened for prostate cancer
(and then by intervention and control groups) [53].
O’Connor (1999) and Legare (2008) used more sophisti-
cated modeling analyses to calculate concordance
[54,55]. Both studies elicited patients’ personal goals and
then used a regression model to examine the extent to
which the values (independent variables) explained the
choices (dependent variable). Although all seven of
these studies also captured patients’ knowledge, none of
them created a composite decision quality score that
reported both informed and concordant choices.
Impact of PtDAs on decision quality
The Cochrane Collaboration’s review results indicate
that: PtDAs improve knowledge by about 14% (a mean
difference of 13.8 out of 100; 95% CI 11.4 to 16.2; n =
26 studies), with greater knowledge gains with more
complex PtDAs; and improve realistic expectations by
74% (relative risk 1.7; 95% CI 1.5 to 2.1; n = 14 studies),
more so when the probabilities are expressed in num-
bers than words. PtDAs also result in fewer people
being undecided, in that more have clear treatment pre-
ference (RR 0.6; 95% CI 0.4 to 0.7; n = 10 studies); and,
in the presence of explicit values clarification, improve
the percentage of informed, values-based choices by 25%
(RR 1.3; 95% CI 1.1 to 1.5; n = 8 studies) [14].
Discussion
The original 2005 publication of the IPDAS Collabora-
tion’s standards highlighted the importance of measuring
the decision-making process and decision quality in order
to understand the effectiveness of PtDAs. The leaders of
the Cochrane Collaboration’s systematic review of decision
aids then used those constructs as an organizing frame-
work for reporting their subsequent results. Since 2005,
many new randomized controlled trials that test the effec-
tiveness of PtDAs have been published, and this growth of
the evidence has strengthened the initial conclusions and
added some new findings.
Many of the findings incorporated in the relevant
chapter on effectiveness that appears in the IPDAS Col-
laboration’s 2005 Original Background Document are
reconfirmed. With respect to the quality of the decision-
making process, PtDAs reduce decisional conflict with
regard to feeling uninformed and unclear about personal
values, and result in more patients playing an active role
in decision making. With respect to core domains of
decision quality, PtDAs improve people’sk n o w l e d g e
regarding options (patients are more informed) and,
when outcome probabilities are included, PtDAs result
in more realistic expectations of risk and benefit.
The recent Cochrane Collaboration’s review includes
additional evidence for decision quality, with new studies
showing that, when compared to simple decision aids,
those with explicit values clarification increase the per-
centage of patients who make an informed, values-based
choice. However, the bulk of the studies (6/8) in this
meta-analysis used the Multidimensional Measure of
Informed Choice approach. Some of these studies used a
variation of MMIC that combines knowledge scores,
scores on the values subscale of the Decisional Conflict
Scale, and the percentage of patients able to state clear
treatment preference. It is possible that these findings are
simply reaffirming, in a composite measure, that PtDAs
improve knowledge and reduce decisional conflict.
Although having a clear intention is important, some of
the studies using MMIC do not provide direct evidence
of increased concordance between patients’ goals and
treatment choices.
There is still limited evidence on two key attributes of
the decision-making process construct—whether deci-
sion aids help patients recognize a decision needs to be
made, and whether PtDAs help patients discuss their
goals and concerns with their health care providers.
Although some survey instruments do contain one or
more items that cover these attributes, none reported
on them separately and, as a result, these could not be
included in the Cochrane Collaboration’s review.
More recent advances in decision quality measurement
are not yet reflected in the Cochrane Collaboration’s
review. For example, Sepucha and colleagues have pub-
lished psychometric analyses of three decision quality
instruments (for osteoarthritis of the knee or hip, her-
niated disc, and breast cancer surgery) that assess the
extent to which patients are informed and receive treat-
ments that match their goals [56-58]. In general, these
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comes, including test-retest reliability, content and discri-
minant validity, acceptability, and feasibility. It will be
important to include these measurement instruments in
trials of PtDAs in order to advance our ability to measure
decision quality.
There are strengths and limitations of this review
worth noting. Our review has drawn upon robust studies
of effectiveness of PtDAs to examine the measurement of
major attributes of two core constructs—the quality of
the decision-making process and decision quality. Two
expert reviewers independently extracted data, with refer-
ence to a third reviewer for any disagreements, and with
reference to source articles for instruments where neces-
sary. The restriction to measures used in RCTs, however,
has resulted in some limitations. First, the review of mea-
surement instruments may have missed instruments that
were not used in RCTs in the Cochrane Collaboration
review (see, for example, Scholl et al. for a review of mea-
sures of SDM)[59]. Second, the RCTs are not designed to
provide details about the active ingredients of the inter-
ventions and about the contextual factors that might act
as barriers or facilitators to use (and, hence, enhance
external validity and generalizability). One way of addres-
sing this issue is through linked qualitative methods,
including process evaluation, the value of which is
increasingly recognized [19,60,61]. Another limitation is
that we used the descriptions of the measures reported in
the publications, and it was not always possible to ascer-
tain what was included in the full instrument or details
on the psychometric properties. Further studies to exam-
ine the quality of the instruments used would be helpful.
The preparation of this paper has been fruitful, in that
it has confirmed evidence to support current IPDAS cri-
teria for evaluating the effect of decision aids on the
decision-making process and decision quality, and it has
identified a number of questions that remain to be
answered. Several questions emerged in our discussions,
which we have summarized below as high-priority over-
arching questions for future research.
How and when should the impact of PtDAs on the
decision-making process and decision quality be
measured?
Our review of the evidence found considerable variability
in the constructs/attributes covered in trials of PtDAs and
in the measurement instruments used. Our discussions
noted the absence of an agreed-upon minimal set of “best”
standardized, validated measures of the decision-making
process and decision quality. There were gaps in the mea-
surement of some attributes, which suggests a need for
the development of new measurement instruments.
Whether it is possible to have one instrument that could
cover all the core decision making process attributes is not
clear, but would be desirable. It will be important for this
work to be done not only with reference to the core attri-
butes, but also with careful consideration of the psycho-
metric properties of measures devised to gauge those
attributes. As researchers seek to develop new measures
or strengthen existing ones, careful attention to strong
clinical and psychometric properties is important [62].
Current measures are mostly patient self-reported
measures, with a dearth of provider-reported, patient-
provider interaction, or concordance measures. Levels of
analysis (e.g., individual versus aggregate levels) need to
be better specified in terms oft h ev a l u eo fi n v e s t m e n t
in decision quality measurement. Theoretical issues
include differentiating between similar constructs and
attributes when measuring and evaluating the impact of
PtDAs, as well as identifying whether the focus of mea-
surement should be around chosen or implemented
options. For example, gaining a deeper understanding
into the relative importance and role of patients’ subjec-
tive perceptions of the decision-making process (such as
feeling informed or even feeling that the decision was
shared with their provider), compared to more objective
measures of knowledge or involvement, will be impor-
tant to explore [63,64].
Additional questions concern specific effects of PtDAs.
For example, in “informing” patients, how much and what
type of patient knowledge is needed to support high qual-
ity decisions? Equally, what is the best time to measure the
impact of PtDAs, in relation to concerns about hindsight
bias (if measured too late) or other influences such as pro-
vider consultation (if measured too soon)?
What are the other key constructs that should be
measured to improve our understanding of the
effectiveness of PtDAs?
This area of discussion focused on potential variants or
extensions of existing PtDAs, and expansion of research
on PtDAs to additional types of outcomes, settings, and
populations. For example, in what situations is it more
appropriate to use a briefer versus more complex PtDA?
Are there certain patients or populations who should
not get PtDAs? What are the active ingredients
(mechanisms) of PtDAs and which are most essential or
important to effectiveness? Given limited attention to
potential harms/adverse effects of PtDAs, should harms
such as bias, cognitive burden, or decision regret be
measured, and, if so, how, when, and under what cir-
cumstances? Beyond evaluating the decision-making
process and decision quality, what is the role of mea-
surement of other factors such as treatment rates, ser-
vice utilization, health inequalities/disparities, literacy,
clinical outcomes, costs, and cost-effectiveness?
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measurement?
Conceptual diversity exists in that multiple theories are
relevant to the development of PtDAs and improving
decision quality; e.g., decision-making theories, informa-
tion-processing theories, and communication theories.
The propositions of each theory may suggest different
outcomes as priorities for evaluation. At present there is
not an agreed-upon minimal set of evaluation measures
in relation to how outcomes from each theory would be
reconciled and/or linked to each other. There is also a
need to assess if decision-making process variables are
predictive of decision quality, and if so, how. Beyond
measurement of the decision-making process and deci-
sion quality, increasingly PtDAs involve the considera-
tion of options with a significant behavior change
component—for example, surgery versus diet and exer-
cise for obesity/weight management. In what way, if at
all, does this behavior change component alter the
approach to evaluating PtDAs? For example, is it also
necessary to assess levels of self-efficacy and motivation
in addition to knowledge and concordance?
A new initiative led by the US National Cancer Insti-
tute, using a web-based Grid-Enabled Measures (GEM)
database, is collating constructs and measures relevant
to shared decision making, including data on their
development, psychometric properties, and availability
[65]. The GEM-SDM database also allows peers to post
informal reviews of the instruments, which will provide
an important source of guidance to researchers in the
field. This initiative has the potential to address some of
the deficits identified in our review, such as providing a
more comprehensive library of available instruments
and, in the future, may help the field move toward con-
sensus on a set of measures.
Conclusions
In conclusion, this IPDAS-stimulated update of the evi-
dence for the effectiveness of PtDAs has re-emphasized
previous findings that PtDAS can improve the decision-
making process and decision quality. Not only has evidence
been strengthened, but also new evidence is emerging with
respect to decision quality and the measurement of values-
choice concordance.
Nonetheless, gaps remain, particularly with respect to
measures of decision quality, which may be addressed
by use of newly developed instruments in ongoing and
future trials. Multiple measures continue to be used,
particularly for measuring the quality of the decision-
making process, with a lack of consensus on a set of
core standard instruments. It will be important to work
toward some level of harmonization of measures in
order to enable better comparisons across studies.
Finally, there are several important questions for future
research and development in t h ea r e ao fm e a s u r e m e n t ;
we will need to tackle these issues in order to help the
field advance.
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